Esomeprazole 40 mg Provides Improved Intragastric Acid Control as Compared with Lansoprazole 30 mg and Rabeprazole 20 mg in Healthy Volunteers

Digestion

Volumn 68, Issue 4, 2003, Pages 184-188

  Wilder Smith, Clive H ^a   Röhss, Kerstin ^b   Nilsson Pieschl, Catharina ^b   Junghard, Ola ^b   Nyman, Lars ^c  

^a Gastrointestinal Unit   (Switzerland)

^b ASTRAZENECA R AND D   (Sweden)

^c IQVIA   (United States)

Author keywords

Esomeprazole; Intragastric acid control, humans; Intragastric pH, humans; Lansoprazole; Proton pump inhibitors; Rabeprazole

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFECT; FEMALE; HELICOBACTER PYLORI; HUMAN; MALE; NORMAL HUMAN; PH MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CROSS-OVER STUDIES; FEMALE; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE;

EID: 1342280463     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000075697     Document Type: Article

References (28)

1. Joelsson B, Johnsson F: Heartburn - The acid test. Gut 1989;30:1523-1525.
2. Hunt RH: Importance of pH control in the management of GERD. Arch Intern Med 1999;159:649-657.
3. Smith JL, Opekun AR, Larkai E, Graham DY: Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology 1989;96:683-689.
4. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH: Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51(suppl 1):56-67.
5. Howden CW: Optimizing the pharmacology of acid control in acid-related disorders. Am J Gastroenterol 1997;92(suppl):17S-19S.
6. Bell NJ, Hunt RH: Progress with proton pump inhibitors. Yale J Biol Med 1992;65:649-657.
7. Blum RA, Shi H, Karol MD, Greski-Rose PA, Hunt RH: The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 1997;19:1013-1023.
8. Chiba N: Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: A systematic overview. Can J Gastroenterol 1997;11(suppl B):66B-73B.
9. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997;112:1798-1810.
10. Hassan-Alin M, Andersson T, Bredberg E, Röhss K: Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000;56:665-670.
11. Lind T, Rydberg L, Kyleback A, Jonsson A, Andersson T, Hasselgren G, Holmberg J, Röhss K: Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000;14:861-867.
12. Röhss K, Hasselgren G, Hedenström H: Effect of esomeprazole 40 mg vs. omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002;47:954-958.
13. Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, D'Amico D, Hamelin B, Joelsson B: Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000;14:1249-1258.
14. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, Marino V, Hamelin B, Levine JG: Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial. Am J Gastroenterol 2001;96:656-665.
15. Hirschowitz BI: A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991;101:1149-1158.
16. Wilder-Smith CH, Gennoni MA, Triller J, Scheurer U, Merki HS: Is fluoroscopic verification of electrode position necessary in ambulatory intragastric pH monitoring? Digestion 1992;52:1-5.
17. Wilder-Smith C, Röhss K, Claar-Nilsson C, Lundin, C: Esomeprazole 40 mg provides faster and more effective acid control than lansoprazole 30 mg in patients with symptoms of gastroesophageal reflux disease. Gastroenterology 2002;122(suppl 1):S1293.
18. Wilder-Smith C, Claar-Nilsson C, Hasselgren G, Röhss K: Esomeprazole provides faster and more effective acid control than rabeprazole 20 mg in patients with symptoms of GERD. Am J Gastroenterol 2001;96(suppl):S45.
19. Wilder-Smith C, Röhss K, Lundin C, Rydholm H: Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg. Gastroenterology 2000;118:A22.
20. Blum RA, Hunt RH, Kidd SL, Shi H, Jennings DE, Greski-Rose PA: Dose-response relationship of lansoprazole to gastric acid antisecretory effects. Aliment Pharmacol Ther 1998;12:321-327.
21. Huang JQ, Goldwater RR, Thomson AB, Chiu YL, Pilmer BL, Hunt RH: Lansoprazole achieves faster control of intragastric acidity than pantoprazole. Gastroenterology 1999;116:2609.
22. Timmer W, Ripke H, Kleist P, Ehrlich A, Wieckhorst G, Lucker PW, Fuder H: Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects. Methods Find Exp Clin Pharmacol 1995;17:489-495.
23. Tolman KG, Sanders SW, Buchi KN, Karol MD, Jennings DE, Ringham GL: The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997;24:65-70.
24. Williams MP, Sercombe J, Hamilton MI, Pounder RE: A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998;12:1079-1089.
25. Willams MP, Blanshard C, Millson C, Sercombe J, Pounder RE: A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects. Ailment Pharmacol Ther 2000;14:691-699.
26. Orlando RC: The pathogenesis of gastroesophageal reflux disease: The relationship between epithelial defense, dysmotility and acid exposure. Am J Gastroenterol 1997;92:3s-5s.
27. Holloway RH, Dent J, Narielvala F, Mackinnon AM: Relationship between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996;38:649-654.
28. Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG: Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis (EE). Am J Gastroenterol 2002;97:575-558.